Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib

Sorafenib is currently the only US Food and Drug Administration (FDA)-approved molecular inhibitor for the systemic therapy of advanced hepatocellular carcinoma (HCC). Aspirin has been studied extensively as an anti-inflammation, cancer preventive and therapeutic agent. However, the potential synerg...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cell Death Discov
Main Authors: Xia, Hongping, Lee, Kee Wah, Chen, Jianxiang, Kong, Shik Nie, Sekar, Karthik, Deivasigamani, Amudha, Seshachalam, Veerabrahma Pratap, Goh, Brian Kim Poh, Ooi, London Lucien, Hui, Kam M
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5592242/
https://ncbi.nlm.nih.gov/pubmed/28900541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddiscovery.2017.58
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares